NCT00675727View on ClinicalTrials.gov

Safety Study of CADI-05 in Patients With Advanced Stage Melanoma

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

December 31, 2010

Conditions
Stage III or Stage IV Melanoma
Interventions
BIOLOGICAL

CADI-05

Two intradermal treatments each week for first 4 weeks followed by one intradermal treatment per week for second 4 weeks.

Trial Locations (1)

18103

Lehigh Valley Hospital, Allentown

Sponsors
All Listed Sponsors
lead

Cadila Pharnmaceuticals

INDUSTRY

NCT00675727 - Safety Study of CADI-05 in Patients With Advanced Stage Melanoma | Biotech Hunter | Biotech Hunter